ONCOLOGY

Key recommendations in hormone-naive metastatic and castration-resistant disease.

The final appraisal decision can be appealed up to 10 July 2020

OS and cancer-specific survival were similar vs long-term ADT.

10-year database study of low- and intermediate-risk patients.

Multigene prostate cancer liquid biopsy is intended for diagnosis, monitoring.

Clinicians should consider these risks in patients unlikely to benefit from nerve sparing.

Final OS analysis of phase 3 PREVAIL study.

Cardiovascular risk was lower with relugolix.

Inconsistent guidelines and challenges of genetic counselling for prostate cancer warrant new recommendations

Final OS analysis of PROSPER trial supports metastasis-free survival as a surrogate of OS.

Results from the UK Biobank cohort study.

Findings from a prospective analysis in UK Biobank.

Meta-analysis of 42 studies.

Leuprorelin products available in a formulation for daily injections are not affected.